Resumo

VILLEGAS GUTIERREZ, Iván. How useful in the daily practice of nephrologists are the new antidiabetics with cadiovascular protection?. Rev. colom. nefrol. [online]. 2017, vol.4, n.1, pp.69-73. ISSN 2500-5006.  https://doi.org/10.22265/acnef.4.1.265.

In recent years, several new antidiabetic drugs have been developed, among which only two have demonstrated superiority in cardiovascular protection. They are liraglutide and empagliflozine, which belong, respectively, to GLP-1 RA and SGLT-2Í. These medications have also shown benefits in kidney protection. However, in a recent survey of the author among nephrologists in a large colombian city, it has been detected that most do not use these drugs. The greater resistance to the limitation in its use is due to the advanced stages of chronic kidney disease where they are contraindicated, but also to the anawareness of their potential benefits. In this regard, the nephrologists accepted they should learn more about these antidiabetic medicines, because the type of patient that is frequently attended in their consultation will undoubtly benefit, and considering they are obligated to handle the diabetic patient directly.

Palavras-chave : liraglutide; empagliflozin; type 2 diabetes; cardioprotection; nephroprotection.

        · resumo em Espanhol     · texto em Inglês | Espanhol     · Inglês ( pdf ) | Espanhol ( pdf )